The cancer biomarker problem
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedCirculating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,559
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Successful 're-biopsy' studies have been carried out and have resulted, for example, in the discovery that patients with lung cancer who relapse during treatment with EGFR inhibitors have acquired mutations in the genetic region encoding the kinase domain of EGFR since the initial biops”
BackgroundEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“In addition, mutations in the genetic region encoding the kinase domain of the epidermal growth-factor receptor (EGFR) predict the sensitivity of lung tumours to erlotinib or gefitini”
BackgroundGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442 · cited 1×
“And, in glioblastoma multiforme, distinct mutations in the genetic region encoding the extracellular domain of EGFR predict sensitivity to EGFR inhibitors but only in cases in which the tumour-suppressor protein PTEN is also intac”
BackgroundSelf-citationDetection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Cited by
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
“A more serious issue relates to the utility of monitoring patients with advanced cancers, either with ctDNA or with other biomarkers (38, 39).”
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Epigenome-wide association studies for common human diseases
Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3000 · Cited by 1,267
Cancer biomarker detection: recent achievements and challenges
Wu, L., & Qu, X. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00370e · Cited by 1,214
Photopharmacology: Beyond Proof of Principle
Velema, W. A., Szymanski, W., & Feringa, B. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja413063e · Cited by 1,178
Geeleher, P., Cox, N. J., & Huang, R. S. (2014) · Genome Biology · doi:10.1186/gb-2014-15-3-r47 · Cited by 890
Antifouling Strategies for Selective In Vitro and In Vivo Sensing
Jiang, C., Wang, G., Hein, R., Liu, N., Luo, X., & Davis, J. J. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00739 · Cited by 598
Exosomes in bodily fluids are a highly stable resource of disease biomarkers
Boukouris, S., & Mathivanan, S. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400114 · Cited by 586
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Mouliere, F., Robert, B., Arnau Peyrotte, E., Del Rio, M., Ychou, M., Molina, F., Gongora, C., & Thierry, A. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023418 · Cited by 567
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer
Rusling, J. F., Kumar, C. V., Gutkind, J. S., & Patel, V. (2010) · The Analyst · doi:10.1039/c0an00204f · Cited by 552
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics
Pekin, D., Skhiri, Y., Baret, J.-C., Le Corre, D., Mazutis, L., Ben Salem, C., Millot, F., El Harrak, A., Hutchison, J. B., Larson, J. W., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20128j · Cited by 540
Taly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 492
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
DNA Methylation Cancer Biomarkers: Translation to the Clinic
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01150 · Cited by 472
Electrical biosensors and the label free detection of protein disease biomarkers
Luo, X., & Davis, J. J. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60077g · Cited by 460
Clinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., & Tavazoie, S. F. (2012) · Cell · doi:10.1016/j.cell.2012.10.028 · Cited by 415
“…at high risk from those at very low risk for metastatic relapse reveals both the cooperativity of these miRNAs and their clinical potential as melanoma biomarkers (Sawyers, 2008) for identifying the subset of patients that might benefit from experimental therapies such as miRNA inhibition therapy.”
Lin, M., Song, P., Zhou, G., Zuo, X., Aldalbahi, A., Lou, X., Shi, J., & Fan, C. (2016) · Nature Protocols · doi:10.1038/nprot.2016.071 · Cited by 388
Systems medicine: the future of medical genomics and healthcare
Auffray, C., Chen, Z., & Hood, L. (2009) · Genome Medicine · doi:10.1186/gm2 · Cited by 387
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
“Selecting the Optimal Kinase Inhibitor Using Dynamic BH3 Profiling In clinical practice, an important application of a potentially powerful, widely applicable predictive biomarker would be to choose from among a panel of possible therapies (Sawyers, 2008).”
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Gervais, L., & Delamarche, E. (2009) · Lab on a Chip · doi:10.1039/b906523g · Cited by 345
Glycans and glycoproteins as specific biomarkers for cancer
Kailemia, M. J., Park, D., & Lebrilla, C. B. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9880-6 · Cited by 341
Translating cancer research into targeted therapeutics
de Bono, J. S., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 335
Integrative analysis of the melanoma transcriptome
Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., Johnson, L. A., Robinson, J., Verhaak, R. G., Sougnez, C., et al. (2010) · Genome Research · doi:10.1101/gr.103697.109 · Cited by 305
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Hou, T., Li, W., Liu, X., & Li, F. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02790 · Cited by 307
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
Thierry, A. R., Mouliere, F., Gongora, C., Ollier, J., Robert, B., Ychou, M., Del Rio, M., & Molina, F. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq421 · Cited by 299
Emerging Technologies for the Clinical Microbiology Laboratory
Buchan, B. W., & Ledeboer, N. A. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00003-14 · Cited by 297
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Multiplex protein assays based on real-time magnetic nanotag sensing
Osterfeld, S. J., Yu, H., Gaster, R. S., Caramuta, S., Xu, L., Han, S.-J., Hall, D. A., Wilson, R. J., Sun, S., White, R. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810822105 · Cited by 288
Making sense of big data in health research: towards an EU action plan
Auffray, C., Balling, R., Barroso, I., Bencze, L., Benson, M., Bergeron, J., Bernal-Delgado, E., Blomberg, N., Bock, C., Conesa, A., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0323-y · Cited by 286
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Karsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A.-C., Smith, V., Adamkewicz, J. I., Christiansen, C., & Leeming, D. J. (2013) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2012.474 · Cited by 279
The molecular pathology of cancer
Harris, T. J. R., & McCormick, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 276
Biomarker detection technologies and future directions
Nimse, S. B., Sonawane, M. D., Song, K.-S., & Kim, T. (2016) · The Analyst · doi:10.1039/c5an01790d · Cited by 275
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
Karsdal, M. A., Manon-Jensen, T., Genovese, F., Kristensen, J. H., Nielsen, M. J., Sand, J. M. B., Hansen, N.-U. B., Bay-Jensen, A.-C., Bager, C. L., Krag, A., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00447.2014 · Cited by 263
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Cancer Biomarkers: Are We Ready for the Prime Time?
Mishra, A., & Verma, M. (2010) · Cancers · doi:10.3390/cancers2010190 · Cited by 236
“biomarkers [7–19].”
Predictive and prognostic molecular markers for cancer medicine
Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., & Print, C. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009360519 · Cited by 210
“The challenge of accessing tumor tissue The uptake of molecular predictive tests in solid tumors has been slower than in leukemia, possibly due to the more difficult access to solid tumor cells [Sawyers, 2008].”
BackgroundMethodInfluentialSimon, R. (2010) · Personalized Medicine · doi:10.2217/pme.09.49 · Cited by 206
Dual-mode electrochemical analysis of microRNA-21 using gold nanoparticle-decorated MoS2 nanosheet
Su, S., Cao, W., Liu, W., Lu, Z., Zhu, D., Chao, J., Weng, L., Wang, L., Fan, C., & Wang, L. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.03.040 · Cited by 205
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel-Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P., Onetto, N., Stein, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Personalized oncology: Recent advances and future challenges
Kalia, M. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.016 · Cited by 186
“[15] Sawyers CL.”
Ocana, A., Vera-Badillo, F., Al-Mubarak, M., Templeton, A. J., Corrales-Sanchez, V., Diez-Gonzalez, L., Cuenca-Lopez, M. D., Seruga, B., Pandiella, A., & Amir, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095219 · Cited by 167
High‐throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification
Zhu, Y., Weiss, T., Zhang, Q., Sun, R., Wang, B., Yi, X., Wu, Z., Gao, H., Cai, X., Ruan, G., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12570 · Cited by 164
Metadata
- Authors
- Sawyers, C. L.
- Venue
- Nature
- Published
- 2008-04
- Volume
- 452
- Issue
- 7187
- Pages
- 548-552
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2050574264
- Cited by
- 983
- References
- 24
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.